Gilead Pullback!Three bear bars is a concern but, with 2 different measured moves objects above and a solid trend upwards, I think its worth a shot for a long. If it is worth anything, the whole industry seems to be trending positively.
Key facts today
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.84USD
5.66 BUSD
27.06 BUSD
1.24 B
About Gilead Sciences, Inc.
Sector
Industry
CEO
Daniel P. O'Day
Website
Headquarters
Foster City
Founded
1987
FIGI
BBG000CKGBP2
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Gilead Sciences (GILD): Will Support Hold or Will We See a Drop?We've neglected Gilead Sciences for a while, but it's time for an update. Unfortunately, our entry looking back wasn't ideal, as the stock has fallen below the 61.8% retracement level. It found support just below the 78.6% level, which marks the bottom of our range. This level was precisely touched,
Gilead Sciences (GILD): Pattern Still Intact—What’s the Plan?Let’s quickly review our open position in $GILD. We’ve managed to turn the whole chart around, and I hope everyone who bought in had the strength to sit it out. It was a close call with the stop loss, but now we’re up significantly, and we’ve moved our stop loss closer to $65.46. So far, we’re up 17
Gilead Sciences (GILD): First Take Profit in a High RangeGilead Sciences is now back trading at the high end of its range, and we’ve decided to take our first profit here. It’s crucial to respect range-bound trading, and there is a strong possibility of a pullback at this point. However, we don’t expect this pullback to reach the lower end of the range ag
Swing Trade Potential Following Completed BottomNASDAQ:GILD has completed its bottom AND sustained the run up from the bottom completion, which provides strong support. The stock is now heading toward the previous resistance highs from January; this is not strong resistance. The type of sideways trend developing now builds energy that can easily
GILD potential Buy setupReasons for bullish bias:
- Price gave LH breakout
- Strong bullish divergence
- Price bounce from support zone
Here are the recommended trading levels:
Entry Level(CMP): 68.30
Stop Loss Level: 60.81
Take Profit Level 1: 76.05
Take Profit Level 2: 83.67
Take Profit Level 3: Open
GILD is BullishPrice was in a strong downtrend, however the bulls woke up and won control of the price action, following bullish RSI divergence on daily time frame, now first higher high and higher low are defined, and if previous higher high is broken, we can expect a bullish rally according to Dow theory. Target
Bullish reversal is a clear confirmationNASDAQ:GILD had a strong bullish buying pressure at the bottom with the support of a volume spike. Furthermore, it has broken out of the downtrend line. Double bottom formation is confirmed and Mid-term stochastic is showing confirmation of oversold together with divergence.
Hence, we will buy on
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where GILD is featured.
Frequently Asked Questions
The current price of GILD is 88.82 USD — it has increased by 0.24% in the past 24 hours. Watch Gilead Sciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Gilead Sciences, Inc. stocks are traded under the ticker GILD.
GILD stock has risen by 0.16% compared to the previous week, the month change is a 6.18% rise, over the last year Gilead Sciences, Inc. has showed a 12.43% increase.
We've gathered analysts' opinions on Gilead Sciences, Inc. future price: according to them, GILD price has a max estimate of 123.00 USD and a min estimate of 69.00 USD. Watch GILD chart and read a more detailed Gilead Sciences, Inc. stock forecast: see what analysts think of Gilead Sciences, Inc. and suggest that you do with its stocks.
GILD reached its all-time high on Jun 24, 2015 with the price of 123.37 USD, and its all-time low was 0.21 USD and was reached on Jun 8, 1994. View more price dynamics on GILD chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
GILD stock is 1.76% volatile and has beta coefficient of 0.33. Track Gilead Sciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Gilead Sciences, Inc. there?
Today Gilead Sciences, Inc. has the market capitalization of 109.92 B, it has decreased by −0.55% over the last week.
Yes, you can track Gilead Sciences, Inc. financials in yearly and quarterly reports right on TradingView.
Gilead Sciences, Inc. is going to release the next earnings report on Nov 6, 2024. Keep track of upcoming events with our Earnings Calendar.
GILD earnings for the last quarter are 2.01 USD per share, whereas the estimation was 1.61 USD resulting in a 25.05% surprise. The estimated earnings for the next quarter are 1.53 USD per share. See more details about Gilead Sciences, Inc. earnings.
Gilead Sciences, Inc. revenue for the last quarter amounts to 6.95 B USD, despite the estimated figure of 6.70 B USD. In the next quarter, revenue is expected to reach 7.01 B USD.
GILD net income for the last quarter is 1.61 B USD, while the quarter before that showed −4.17 B USD of net income which accounts for 138.71% change. Track more Gilead Sciences, Inc. financial stats to get the full picture.
Yes, GILD dividends are paid quarterly. The last dividend per share was 0.77 USD. As of today, Dividend Yield (TTM)% is 3.47%. Tracking Gilead Sciences, Inc. dividends might help you take more informed decisions.
Gilead Sciences, Inc. dividend yield was 3.70% in 2023, and payout ratio reached 66.62%. The year before the numbers were 3.40% and 80.25% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 1, 2024, the company has 18.00 K employees. See our rating of the largest employees — is Gilead Sciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Gilead Sciences, Inc. EBITDA is 12.88 B USD, and current EBITDA margin is 45.96%. See more stats in Gilead Sciences, Inc. financial statements.
Like other stocks, GILD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Gilead Sciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Gilead Sciences, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Gilead Sciences, Inc. stock shows the strong buy signal. See more of Gilead Sciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.